CDT Equity highlights Sarborg quantum-assisted coformer selection for solid-form drug development

Conduit Pharmaceuticals

Conduit Pharmaceuticals

CDT

0.00
  • CDT Equity highlighted Sarborg’s expansion of its Signature Intelligence platform into quantum-assisted coformer selection via SarborgQ.
  • Quantum computing, agentic AI, and proprietary datasets target faster solid-form development, improved selection decisions, and new patentable co-crystal opportunities.
  • Sarborg has built a database of more than 850 coformers; initial deployment targets its internal IP portfolio before offering tools to external partners.
  • CDT framed the move as a milestone for SarborgQ, aimed at accelerating IP generation, improving development efficiency, and widening commercial opportunities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDT Equity Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.